Close Menu

R&D, Ruh-Roh

Pharmaceutical companies are watching their R&D costs go up, up, up, as they search for the next blockbuster drug amid dried-up pipelines and upcoming patent cliffs, reports The Guardian's Julia Kollewe. A recent Deloitte report shows that the cost of bringing a drug to market for the world's 12 biggest pharma companies has risen by more than 25 percent to about $1 billion this year from about $830 million in 2010, Kollewe says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.